HRD相关特征3可预测晚期输卵管-卵巢高级别浆液性癌的临床结局
前瞻性观察性试验纳入165例晚期输卵管-卵巢高级别浆液性癌患者,于诊断时和新辅助化疗后采集456份新鲜组织行全基因组测序,评估单碱基置换特征3(Sig3)作为同源重组缺陷(HRD)生物标志物的可用性。Sig3呈双峰分布,无需任意截断值,可在癌细胞比例低至10%的样本中评估,且在新辅助化疗期间稳定。诊断时Sig3阳性患者无进展生存期和总生存期均显著优于阴性患者。
要点
- Sig3在晚期HGSC中呈双峰分布,无需任意截断值,可在癌细胞比例低至10%的样本中评估。
- 诊断时74例(45%)为HRD(Sig3+),91例(55%)为HR proficient(HRP,Sig3-)。
- Sig3+患者PFS和OS均长于Sig3-患者(22 vs 13个月和51 vs 34个月,均p<0.001)。
核心结论
- Sig3是晚期HGSC的预后标志物,也是HRD患者分层的有用工具。
研究设计与样本
- 前瞻性观察性试验纳入165例晚期输卵管-卵巢高级别浆液性癌患者,于诊断时和新辅助化疗后从多个腹腔区域采集456份新鲜组织行全基因组测序,通过独立拟合COSMIC v3.2参考特征评估Sig3,并与HR瘢痕检测比较,采用Kaplan-Meier和Cox回归分析PFS和OS。
主要发现
- Sig3呈双峰分布,无需HR瘢痕检测中典型的任意截断值,可在癌细胞比例低至10%的样本中评估,且在多份样本间一致并在新辅助化疗期间稳定。
- 诊断时74例(45%)患者为HRD(Sig3+),91例(55%)为HR proficient(HRP,Sig3-)。
- Sig3+患者PFS和OS均长于Sig3-患者(22 vs 13个月和51 vs 34个月,均p<0.001)。
- 在BRCAwt患者中,Sig3成功区分出预后差的HRP组(Sig3+患者PFS 19个月 vs Sig3-患者13个月,p<0.001)。
- 诊断时Sig3不能预测首次复发时的化疗反应;Sig3与HR瘢痕检测的患者水平一致率为87%,两种检测均判定为HRD的患者中位PFS最长。
临床怎么用
- 作者认为Sig3是晚期HGSC的预后标志物,也是HRD患者分层的有用工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated usability of single base substitution signature 3 (Sig3) as a biomarker for homologous recombination deficiency (HRD) in tubo-ovarian high-grade serous carcinoma (HGSC). MATERIALS AND METHODS: This prospective observational trial includes 165 patients with advanced HGSC. Fresh tissue samples (n = 456) from multiple intra-abdominal areas at diagnosis and after neoadjuvant chemotherapy (NACT) were collected for whole-genome sequencing. Sig3 was assessed by fitting samples independently with COSMIC v3.2 reference signatures. An HR scar assay was applied for comparison. Progression-free survival (PFS) and overall survival (OS) were studied using Kaplan-Meier and Cox regression analysis. RESULTS: Sig3 has a bimodal distribution, eliminating the need for an arbitrary cutoff typical in HR scar tests. Sig3 could be assessed from samples with low (10%) cancer cell proportion and was consistent between multiple samples and stable during NACT. At diagnosis, 74 (45%) patients were HRD (Sig3+), while 91 (55%) were HR proficient (HRP, Sig3-). Sig3+ patients had longer PFS and OS than Sig3- patients (22 vs. 13 months and 51 vs. 34 months respectively, both p < 0.001). Sig3 successfully distinguished the poor prognostic HRP group among BRCAwt patients (PFS 19 months for Sig3+ and 13 months for Sig3- patients, p < 0.001). However, Sig3 at diagnosis did not predict chemoresponse anymore in the first relapse. The patient-level concordance between Sig3 and HR scar assay was 87%, and patients with HRD according to both tests had the longest median PFS. CONCLUSIONS: Sig3 is a prognostic marker in advanced HGSC and useful tool in patient stratification for HRD.
引用
- Koskela H, Li Y, Joutsiniemi T, et al. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma. Gynecol Oncol. 2023. PMID: 38061276. doi:10.1016/j.ygyno.2023.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。